

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problems Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>6</sup> : C07K 14/205 // A61K 39/106</p>	<p>A1</p>	<p>(11) International Publication Number: WO 96/38475 (43) International Publication Date: 5 December 1996 (05.12.96)</p>
<p>(21) International Application Number: PCT/SE96/00727 (22) International Filing Date: 3 June 1996 (03.06.96) (30) Priority Data: 9502007-9 1 June 1995 (01.06.95) SE 9601085-5 21 March 1996 (21.03.96) SE (71) Applicant (for all designated States except US): ASTRA AKTIEBOLAG [SE/SE]; S-151 85 Södertälje (SE). (72) Inventors; and (75) Inventors/Applicants (for US only): BÖLIN, Ingrid [SE/SE]; Oljekvarnsgatan 13 A, S-414 65 Göteborg (SE). SVENNER- HOLM, Ann-Mari [SE/SE]; Korvettgatan 1 D, S-426 74 Västra Frölunda (SE). (74) Agent: ASTRA AKTIEBOLAG; Patent Dept., S-151 85 Södertälje (SE).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p>
<p>(54) Title: <b>HELICOBACTER PYLORI ANTIGENS AND VACCINE COMPOSITIONS</b></p> <p>(57) Abstract</p> <p>The present invention relates to recombinant polypeptides which constitute <i>Helicobacter pylori</i> surface-exposed antigens with an approximate molecular weight of 29 kDa. The invention furthermore provides nucleic acid molecules coding for the said polypeptides, as well as vectors and host cells comprising such nucleic acid molecules. The said recombinant polypeptides are useful for the diagnosis of <i>H. pylori</i> infections and for the manufacture of vaccine compositions which will elicit a protective immune response against such infections, said vaccine compositions being suitable for both therapeutic and prophylactic use.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

*Helicobacter pylori* antigens and vaccine compositions.

#### TECHNICAL FIELD

5     The present invention provides recombinant polypeptides which constitute *Helicobacter pylori* antigens, said antigens being expressed on the surface of both dividing (bacillary) forms as well as resting (coccoid) forms of *H. pylori*, and giving rise to both systemic and local (mucosal) production of antibodies. The invention furthermore provides nucleic acid molecules  
10    coding for the said polypeptides, as well as vectors and host cells comprising such nucleic acid molecules. The said recombinant polypeptides are useful for the diagnosis of *H. pylori* infections and for the manufacture of vaccine compositions which will elicit a protective immune response against such infections, said vaccine compositions being suitable  
15    for both therapeutic and prophylactic use.

#### BACKGROUND ART

20    The gram-negative bacterium *Helicobacter pylori* is an important human pathogen, involved in several gastroduodenal diseases. Colonization of gastric epithelium by the bacterium leads to active inflammation and progressive chronic gastritis, with a greatly enhanced risk of progression to peptic ulcer disease.

25    In order to colonize the gastric mucosa, *H. pylori* uses a number of virulence factors. Such virulence factors comprise several adhesins, with which the bacterium associates with the mucus and/or binds to epithelial cells; ureases which helps to neutralize the acid environment; and  
30    proteolytic enzymes which makes the mucus more fluid.

-2-

Despite a strong apparent host immune response to *H. pylori*, with production of both local (mucosal) as well as systemic antibodies, the pathogen persists in the gastric mucosa, normally for the life of the host. The reason for this is probably that the spontaneously induced immune-  
5 response is inadequate or directed towards the wrong epitopes of the antigens.

In order to understand the pathogenesis and immunology of *H. pylori* infections, it is of great importance to define the antigenic structure of this  
10 bacterium. In particular, there is a need for characterization of surface-exposed (like adhesins) and secreted proteins which, in many bacterial pathogens, have been shown to constitute the main virulence factors, and which can be useful for the diagnosis of *H. Pylori* and in the manufacture of vaccine compositions.

15 Cloning of the gene *hpaA*, which codes for a 20 kDa receptor-binding subunit of the *N*-acetylneuraminyllactose-binding fibrillar hemagglutinin (NLBH) of *H. pylori*, has been disclosed by Evans et al. (1993) J. Bacteriol. 175, 674-683.

20 Monoclonal antibodies (MAbs) against membrane preparations of *H. pylori* have been disclosed by Bölin et al. (1995) J. Clin. Microbiol. 33, 381-384. One of these MAbs, designated HP30-1:1:6, reacted with a 30 kDa protein which was shown to be exposed on the surface of intact bacteria and to  
25 have properties like that of an adhesin.

Whenever stressed or threatened, the *H. pylori* cell transforms from a bacillary to a coccoid form. In the coccoid form, the *H. pylori* cell is much less sensitive to antibiotics and other anti-bacterial agents. Circumstantial  
30 evidence indicate the *H. pylori* might be transmitted between individuals in this form, possibly via water or direct contact. An efficient vaccine composition should therefore elicit an immune response towards both the

-3-

coccoid and the bacillary form of *H. pylori*. Since systemic immunity probably only plays a limited role in protection against mucosal infections, it is also important that the vaccine composition will enhance protective immune mechanisms locally in the stomach.

5

#### PURPOSE OF THE INVENTION

The purpose of this invention is to provide an antigenic *H. pylori* polypeptide which can be useful i.a. for eliciting a protective immune response against, and for diagnosis of, *H. pylori* infection. This purpose has been achieved by the recombinant cloning of a *H. pylori* gene which encodes a surface-exposed protein. The nucleic acid sequence of this gene is similar to the sequence of the *hpaA* gene as published by Evans et al. (1993) in the Journal of Bacteriology, vol. 175, 674-683. However, while the *hpaA* gene was reported to code for a 20 kDa protein, it has surprisingly been found that the DNA molecule according to the invention encodes a polypeptide with a molecular weight of 29 kDa.

The 29 kDa polypeptide is shown to be an antigenic protein which is expressed in all strains of *H. pylori*, also in coccoid forms of the bacterium, and which is able to induce a mucosal as well as a systemic immune-response in a host measured as antibody production. The 29 kDa polypeptide is expressed by all *H. pylori* strains tested and antibodies created towards this protein do not cross-react with common endogenous human bacteria of other species or with selected human tissues including the gastric mucosa. Thus being an essential, well conserved adhesin with immunogenic properties, the 29 kDa polypeptide will be useful both for the detection of *H. pylori* infections as well as for the manufacture of vaccine compositions, which when given in an appropriate pharmaceutical formulation will elicit a protective or therapeutic immune response against such infections.

The experimental data below thus indicates that the 29 kDa *H. pylori* protein is important for *H. pylori* colonization and/or persistence of infection, since binding of a monoclonal antibody for the 29 kDa protein results in complete inhibition of colonisation of *H. pylori* in mice. Furthermore, the 29 kDa *H. pylori* protein, when used as an oral immunogen, acts as a stimulator of an immune response leading to a significant reduction of colonisation of *H. pylori* in mice which were infected with *H. pylori* 1 month prior to immunization.

10

#### BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1: Restriction enzyme map of plasmid pAE1 containing the 1.7 kb fragment of *H. pylori* encoding the 29 kDa polypeptide. Hatched bar indicates the position of the structural gene. The location of the T3 and T7 promoter sequences are shown above the black bars indicating the vector.

Fig. 2: Plasmid maps of pS860, pS861, pS862 and pS863.  
Filled arrows: *lac* operon promoter (Plac) or bacteriophage T7 RNA Polymerase promoter (T7promoter). Grey fill: PCR generated 5'-end or 3'-end of the 29 kDa gene. Terminator: T7 transcription terminator. Ori: pBR322 plasmid replication origin.

Fig. 3: Effect of monoclonal antibodies on the colonisation of *H. pylori* in BALB/c mice.

Fig. 4: Therapeutic oral immunization of *H. pylori* infected BALB/c mice.

## DISCLOSURE OF THE INVENTION

Throughout this description and in particular in the following examples, the terms "standard protocols" and "standard procedures", when used in the context of molecular cloning techniques, are to be understood as protocols and procedures found in an ordinary laboratory manual such as: Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) Molecular Cloning: A laboratory manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.

10

In a first important aspect, this invention provides a recombinant polypeptide which has an amino acid sequence identical with, or substantially similar to, a *Helicobacter pylori* surface-exposed antigen with an approximate molecular weight of 29 kDa.

15

The said surface-exposed antigen according to the invention has i.a. the following important properties:

- It is an adhesin, which is important for the colonization of the gastric mucosa;
- 20 • It is expressed on the surface of both dividing (bacillary) forms as well as resting (coccoid) forms of *H. pylori*;
- It is a strong antigen giving rise to both systemic and local (mucosal) production of antibodies;
- It is conserved in all tested strains of *H. pylori*;
- 25 • Antibodies to the 29 kDa polypeptide do not cross-react with a number of different non-helicobacter bacteria, or with selected human tissues, including the gastric mucosa;
- The 29 kDa polypeptide is lipidated and thus post-translationally modified. This feature of the polypeptide may be of importance for its immunogenicity and for its proper exposure on the surface of *H. pylori*. It is known in the art that lipid modification can be essential
- 30



-6-

for the immunological properties of bacterial lipoproteins (see Weis, J.J. et al. (1994) Infection and Immunity, vol. 62, 4632-4636).

- It is a putative virulence-factor, whereby the term "virulence factor" is to be understood a molecule specifically involved in adherence of *H. pylori* to the epithelial surface of the gastric mucosa and / or in the establishment and maintenance of *H. pylori* infection.

In a preferred form, the said polypeptide has an amino acid sequence according to positions 1-260, or 28-260, in SEQ ID NO: 2 or 4 of the Sequence Listing. As further described in the Experimental Section, it is believed that positions 1-260 in SEQ ID NO: 2 and 4 represent the uncleaved protein, while positions 1-27 represent a signal sequence and positions 28-260 represent the mature polypeptide. The only difference between SEQ ID NO: 2 and SEQ ID NO: 4 is that SEQ ID NO: 2 has a Ser residue in position 222, while SEQ ID NO: 4 has an Arg residue in the same position.

However, the polypeptide according to the invention is not to be limited strictly to a polypeptide with an amino acid sequence identical with the above mentioned positions in SEQ ID NO: 2 or 4 in the Sequence Listing. Rather the invention encompasses polypeptides carrying modifications like substitutions, small deletions, insertions or inversions, which polypeptides nevertheless have substantially the properties of the 29 kDa polypeptide according to the invention. Such properties include the ability to elicit a mucosal as well as systemic immune-response against *H. pylori* in a mammal host; the ability to work as an adhesin; and the presence of the polypeptide in both bacillary and coccoid forms of *H. pylori*.

Included in the invention are consequently polypeptides, the amino acid sequence of which is at least 90% homologous, preferably at least 95% homologous, with the amino acid sequence shown as positions 1-260, or positions 28-260, in SEQ ID NO: 2 or 4, in the Sequence Listing, which

-7-

polypeptides nevertheless have substantially the biological activities of the 29 kDa polypeptide according to the invention.

5 Included in the invention are also peptides, with a length of at least 5 amino acids, which comprise an immunogenic epitope of the 29 kDa polypeptide according to the invention and retains the ability to elicit an immune response against *H. pylori* bacteria in a mammal host. Such epitope(s) can be presented alone or in the form of fusion proteins, where the epitope is fused to an inert or immunologically active carrier  
10 polypeptide. The identification of these epitopes will be based on the presence of host-generated antibodies towards different segments of the 29 kDa polypeptide.

15 One way of obtaining structural information on the epitopes of the 29 kDa polypeptide is the production and characterisation of monoclonal antibodies binding to the polypeptide, followed by mapping of epitopes by e.g. Pepscan analysis. Monoclonal antibodies can be produced by standard methods, such as those described by De St. Groth (1980) in *J. Immunol. Methods*, vol. 35, 1-21.

20 In another aspect, the invention provides an isolated and purified nucleic acid molecule which has a nucleotide sequence coding for a polypeptide as defined above. In a preferred form of the invention, the said nucleic acid molecule is a DNA molecule which has a nucleotide sequence identical  
25 with SEQ ID NO: 1 or 3 of the Sequence Listing. However, the DNA molecule according to the invention is not to be limited strictly to the sequence shown as SEQ ID NO: 1 or 3. Rather the invention encompasses DNA molecules carrying modifications like substitutions, small deletions, insertions or inversions, which nevertheless encode polypeptides having  
30 substantially the biochemical activity of the 29 kDa polypeptide according to the invention. It will be known to the skilled person that A ↔ G and T ↔ C substitutions, with no effect on the amino acid sequence, are not

unusual in *H. pylori*. The only difference between SEQ ID NO: 1 and SEQ ID NO: 3 is that SEQ ID NO: 1 has an A residue in position 1458, while SEQ ID NO: 3 has a C residue in the same position.

- 5 Included in the invention are also DNA molecules which nucleotide sequences are degenerate, because of the genetic code, to the nucleotide sequence shown as SEQ ID NO: 1 or 3. Since there are 64 possible codons, but only 20 natural amino acids, most amino acids are coded for by more than one codon. This natural "degeneracy", or "redundancy", of the genetic
- 10 code is well known in the art. It will thus be appreciated that the DNA sequence shown in the Sequence Listing is only an example within a large but definite group of DNA sequences which will encode the polypeptide as described above.
- 15 Consequently, the inventions includes an isolated nucleic acid molecule selected from:
- (a) nucleic acid molecules comprising a nucleotide sequence which is identical with, or substantially similar to, positions 796-1572 or 874-1572 in SEQ ID NO: 1 or 3 in the Sequence Listing;
- 20 (b) nucleic acid molecules comprising a nucleotide sequence capable of hybridizing to a nucleotide sequence complementary the polypeptide coding region of a DNA molecule as defined in (a) and which codes for a polypeptide according to the invention, or a functionally equivalent modified form thereof; and (c) nucleic acid molecules comprising a nucleic
- 25 acid sequence which is degenerate as a result of the genetic code to a nucleotide sequence as defined in (a) or (b) and which codes for a polypeptide according to the invention, or a functionally equivalent modified form thereof.
- 30 A further aspect of the invention is a vector which comprises the nucleic acid molecule according to the invention. Such a vector can preferably be

the plasmid vector pAE1 (Deposited under the Budapest Treaty under accession No. NCIMB 40732).

5 A vector according to the invention can also be a replicable expression vector which carries and is capable of mediating the expression of a nucleic acid molecule according to the invention. In the present context the term "replicable" means that the vector is able to replicate in a given type of host cell into which it has been introduced. Examples of vectors are viruses such as bacteriophages, cosmids, plasmids and other recombination  
10 vectors. Nucleic acid molecules are inserted into vector genomes by standard methods known in the art. An expression vector according to the invention can preferably be any one of the vectors pAL30:1, pAL30:2, pAL30:3, pAL30:4 or, more preferably, pS863.

15 Included in the invention is also a host cell harbouring a vector according to the invention. Such a host cell can be a prokaryotic cell, a unicellular eukaryotic cell or a cell derived from a multicellular organism. The host cell can thus e.g. be a bacterial cell such as an *E. coli* cell; a cell from a yeast such as *Saccharomyces cerevisiae* or *Pichia pastoris*, or a mammalian cell.  
20 The methods employed to effect introduction of the vector into the host cell are standard methods well known to a person familiar with recombinant DNA methods.

In another aspect, the invention provides a process for production of a  
25 polypeptide as defined above, said method comprising culturing a host cell transformed with an expression vector as defined above, under conditions whereby said polypeptide is produced, and recovering said polypeptide.

The medium used to grow the cells may be any conventional medium  
30 suitable for the purpose. A suitable vector may be any of the vectors described above, and an appropriate host cell may be any of the cell types listed above. The methods employed to construct the vector and effect

-10-

introduction thereof into the host cell may be any methods known for such purposes within the field of recombinant DNA. The recombinant polypeptide expressed by the cells may be secreted, i.e. exported through the cell membrane, dependent on the type of cell and the composition of the vector.

If the polypeptide is produced intracellularly by the recombinant host, i.e. is not secreted by the cell, it may be recovered by standard procedures comprising cell disruption by mechanical means, e.g. sonication or homogenization, or by enzymatic or chemical means followed by purification. In order to be secreted, the DNA sequence encoding the polypeptide should be preceded by a sequence coding for a signal peptide, the presence of which ensures secretion of the polypeptide from the cells so that at least a significant proportion of the polypeptide expressed is secreted into the culture medium and recovered.

A further aspect of the invention is a polypeptide according to the invention for use in therapy, for use in the diagnosis of *Helicobacter pylori* infection in a mammal, including man, and for use as a therapeutic or prophylactic vaccine.

Another important aspect of the invention is a vaccine composition for inducing a protective immune response in a mammal, including humans, against the bacillary and/or coccoid form of *Helicobacter pylori*. Such a vaccine composition comprises an immunogenically effective amount of a polypeptide as defined above, including at least a part of the 29 kDa polypeptide comprising an immunogenic epitope, or a modified form of said polypeptide which retains the capability to induce protective immunity against *Helicobacter pylori* infection. The term "modified form" includes, but is not restricted to, forms of the polypeptide which are post-translationally modified, e.g. lipidated. It is believed that the 29 kDa protein is lipidated, cf. Example 4 below.

-11-

The vaccine composition comprises optionally also a pharmaceutically acceptable carrier or diluent, or other immunologically active antigens for prophylactic or therapeutic use. Physiologically acceptable carriers and diluents are well known to those skilled in the art and include e.g.  
5 phosphate buffered saline (PBS), or, in the case of oral vaccines,  $\text{HCO}_3^-$  based formulations or enterically coated powder formulations.

The vaccine composition can optionally include or be administered together with acid secretion inhibitors, preferably proton pump inhibitors  
10 (PPIs), e.g. omeprazole. The vaccine can be formulated in known delivery systems such as liposomes, ISCOMs, cochleates, etc. (see e.g. Rabinovich et al. (1994) Science 265, 1401-1404) or be attached to or included into polymer microspheres of degradable or non-degradable nature. The antigens could be associated with live attenuated bacteria, viruses or  
15 phages or with killed vectors of the same kind.

As will be demonstrated in the Experimental Section below, a vaccine composition according to the invention can be used for both therapeutic and prophylactic purposes. The vaccine composition according to the  
20 invention is preferably administered to any mammalian mucosa exemplified by the buccal, the nasal, the tonsillar, the gastric, the intestinal (small and large intestine), the rectal and the vaginal mucosa. The mucosal vaccines can be given together with for the purpose appropriate adjuvants. The vaccine can also be given parenterally, by subcutaneous,  
25 intracutaneous or intramuscular route, optionally together with the appropriate adjuvant.

An alternative approach for creating an immune response against the 29 kDa polypeptide is to use the approach known as "nucleic acid  
30 vaccination" or "naked DNA" vaccination. It is known in the art that injection into muscle of plasmid DNA encoding an antigen of interest can result in sustained expression of the antigen and generation of an immune

response (see e.g. Rabinovich et al. *supra*). Several routes of administration are possible, such as parental, mucosal or via a "gene-gun" that delivers tiny amounts of DNA-coated gold beads (Fynan et al. (1993) Proc. Natl. Acad. Sci. U.S.A. 90, 11478-11482).

5

Thus, a nucleic acid molecule according to the invention can be expressed in plasmid comprising a suitable eukaryotic promoter. This "naked DNA" can then be injected intramuscularly or given intradermally via a "gene-gun". Epitopes of the expressed protein will be expressed by MHC  
10 molecules on the surface of the cells and trigger an immune response. Consequently, nucleic acid molecules and vectors as disclosed in the previous paragraphs for use in therapy, in particular for use as a vaccine, are further aspects of the invention. The use of such nucleic acid molecules and vectors in the manufacture of compositions for treatment, prophylaxis  
15 or diagnosis of *Helicobacter pylori* infection are also further aspects of the invention.

Yet another aspect of the invention is the use of a polypeptide as defined above, or a modified form of said polypeptide which retains the capability  
20 to induce protective immunity against *Helicobacter pylori* infection, in the manufacture of a compositions for the treatment, prophylaxis or diagnosis of *Helicobacter pylori* infection. Such compositions include in particular a vaccine composition eliciting a protective immune response against the bacillary and/or coccoid form of *Helicobacter pylori*. Included in the  
25 invention is also the said use in the manufacture of a diagnostic kit for diagnosis of *Helicobacter pylori* infection. Such a diagnostic kit is further described below.

In a further aspect, the invention provides a method of eliciting in a  
30 mammal, including man, a protective immune response against *Helicobacter pylori* infection, said method comprising the step of administering to the said mammal an immunologically effective amount of a vaccine

- composition as defined above. The term "immunologically effective amount" is intended to mean an amount which elicit a significant protective *Helicobacter pylori* response, which will eradicate a *H. pylori* infection in an infected mammal or prevent the infection in a susceptible mammal. Typically an immunologically effective amount would comprise approximately 1 µg to 100 mg, preferably approximately 10 µg to 10 mg, of *H. pylori* antigen for oral administration, or approximately less than 100 µg for parenteral administration.
- 10 Another aspect of the invention is a method of *in vitro* diagnosis of *Helicobacter pylori* infection, comprising at least one step wherein a polypeptide as defined above, including a part of the 29 kDa polypeptide which part comprises an immunogenic epitope, is used. The polypeptide can optionally be labelled and/or coupled to a solid support. A method of
- 15 diagnosis can e.g. comprise the steps (a) contacting a said polypeptide, optionally bound to a solid support, with a body fluid taken from a mammal; and (b) detecting antibodies from the said body fluid binding to the said polypeptide. Preferred methods of detecting antibodies are ELISA (Enzyme linked immunoabsorbent assay) methods which are well known
- 20 in the art.
- In yet another aspect, the invention provides a diagnostic kit for the detection of *Helicobacter pylori* infection in a mammal, including man, comprising components which enable a diagnosis method as exemplified
- 25 above to be carried out.



## EXAMPLES

EXAMPLE 1: Cloning and expression of a 29 kDa polypeptide from *H. pylori*

5

*1.1. Bacterial strains, vectors and growth conditions*

*H. pylori* CCUG 17874 (= NTCC 11637) was grown on horse blood agar plates in an microaerophilic atmosphere. *E. coli* strains XL1-Blue MRF' and  
10 XL0LR (Stratagene, La Jolla, California) were used as host strains for cloning experiments and were grown in Luria-Bertani broth (LB) or NZY medium supplemented with 0.2% maltose and 10 mM MgSO<sub>4</sub> when used for lambda infection. The lambda expression vector ZAP Express™ and its phagemid derivative pBK-CMV were obtained from Stratagene.

15

*1.2. DNA techniques*

Chromosomal DNA from *H. pylori* 17874 was prepared by suspending bacteria from plates incubated for 48 h in 50 mM Tris-Cl, pH 8.0, 25%  
20 sucrose, 50 mM EDTA containing 10 mg/ml lysozyme, and 5 ng/ml DNase-free RNase (Boehringer Mannheim Scandinavia AB, Bromma, Sweden). The suspension was incubated for 10 min at +37°C. An equal volume of lysis buffer (0.4% Triton X100 in 50 mM Tris-Cl, pH 8.0; and 62.5 mM EDTA) was added and the suspension was incubated at room  
25 temperature until a noticeable lysis of the bacteria occurred. The suspension was then extracted in three steps, with buffered phenol (pH 8.0), phenol/chloroform and chloroform, respectively. The DNA was precipitated from the aqueous phase and dissolved in TE-buffer (10 mM Tris-Cl, pH 8.0; and 1 mM EDTA).

30

Restriction enzymes were purchased from Boehringer Mannheim Scandinavia AB and used according to the manufacturers instructions.

Plasmids and lambda DNA were purified with Wizard kits (Promega, Madison, Wisconsin). Sequencing was performed using the Sequenase 2.0 kit (Amersham Sweden AB, Solna, Sweden). Oligonucleotides were purchased from Innovagen, Lund, Sweden. PCR was performed using Taq DNA polymerase (Boehringer-Mannheim Scandinavia AB).

### 1.3. Construction of a *H. pylori* genomic library

Chromosomal DNA fragments in the size range 2-12 kb were purified from partially *Sau3A*-cleaved *H. pylori* 17874 DNA and cloned into *Bam*HI digested ZAP Express™ vector as described in the Stratagene protocol. Following *in vitro* packaging, the library was titrated by infecting strain XL-1 Blue MRF and plated onto indicator plates containing isopropyl-β-D-thiogalactopyranoside (IPTG) and 5-bromo-4-chloro-3-indolyl-β-D-galactopyranosid (X-Gal). The titer of the library was  $1.2 \times 10^6$  PFU/ml with 85% recombinants.

Plaques expressing the 29 kDa polypeptide were detected by immunological screening using MAb HP30-1:1:6 (Bölin et al. (1995) J. Clin. Microbiol. 33, 381-384) according to standard methods. Positive plaques were isolated and the plating and screening with the MAb was repeated until plaque purity was obtained. The conversion to the phagemid form of the ZAP Express clones was accomplished using the ExAssist protocol (Stratagene).

### 1.4. Immunoblotting and dot blot test

Overnight cultures of *E. coli* XL0LR containing plasmids with cloned inserts from *H. pylori* 17874 depicted in Fig. 1, were diluted 1:100 in 5 ml of LB medium with 50 mg/ml kanamycin. The cultures were incubated at +37°C until the OD at 600 nm was 0.7. IPTG was added to a final concentration of 1 mM and the bacteria were grown for additional 2 h.

Cultures without IPTG were grown similarly. The cultures were centrifuged and resuspended in 1/10 of the volume. Ten µl of the suspension were mixed with an equal volume of 2X sample buffer, boiled and analysed by SDS-PAGE. Strain XLOLR, grown in the same way but without kanamycin, served as a negative control. A suspension of *H. pylori* 17874 in PBS (OD at 600 nm = 1.0) was used as a positive control.

After immobilization of the protein profiles on nitro-cellulose sheets, reaction with the 29 kDa polypeptide-specific MAb HP30-1:1:6 diluted 1:10 was carried out as described previously (Bölin et al., 1995) and bound antibodies were detected by using anti-mouse IgG labelled with peroxidase. Filters were developed with hydrogen peroxide substrate and 4-chloronaphthol chromogen (BioRad Svenska AB).

The dot blot test was performed using overnight cultures of the above strains. Two µl of a suspension were spotted on nitrocellulose filters, air-dried and incubated with MAb HP30-1:1:6 diluted 1:10 for one h. Subsequent steps were carried out as described for immunoblotting.

#### 1.5. Molecular cloning

Partially digested chromosomal DNA from *H. pylori* strain 17874 were cloned into a lambda expression vector (ZAP Express™). Four plaques expressing the 29 kDa polypeptide were detected after screening of 24 000 plaques for reaction with the 29 kDa polypeptide-specific MAb. The positive plaques were purified and the size of the cloned inserts were examined by digestion of DNA-preparations with *Xba*I and *Sal*I. The inserts were from 3.7 to 1.78 kb in size. After *in vivo* excision of the pBK-CMV phagemids from the four positive plaques, restriction enzyme maps were constructed and compared with the inserts in the lambda vector. The phagemids were found to contain overlapping DNA-fragments with the

-17-

same size as in the lambda vector. Most of the restriction enzymes tested, except for *Sma*I and *Nhe*I, did not cleave the cloned fragments.

5 The restriction map of the smallest cloned 1.7 fragment (pAE1) that were...  
further analyzed is shown in Fig. 1. One of the cloned inserts were in the  
opposite direction with regard to the vector promoter. When whole cell  
extracts of the *E. coli* strains containing these plasmids were analysed in  
immunoblotting with MAb HP30-1:1:6, they were all found to express a  
polypeptide with the same molecular weight as *H. pylori* 17874. No  
10 difference in expression of the 29 kDa polypeptide was seen when the  
vector promoter was induced with IPTG. This indicated that the gene was  
transcribed from its own promoter. Three subclones containing the DNA  
fragments indicated in Fig. 1 were constructed and examined for  
expression of the 29 kDa polypeptide. None of the clones expressed the  
15 polypeptide. When XL0LR (pAE1) were tested in the dot blot assay (Bölin  
et al., 1995) and compared with *H. pylori*, it was found to be weakly  
positive indicating that some of the expressed polypeptide may be exposed  
on the surface.

#### 20 1.6. Analysis of the DNA sequence

Both strands of the 1.7 kb insert of pAE1 and the subclones were  
sequenced using T3- and T7-specific primers and, when necessary,  
supplemented with specific primers to cover regions of the sequence not  
25 available with the standard primers. The computer analysis showed that  
the sequence (SEQ ID NO: 1) contained an open reading frame (ORF) of  
780 bp on one strand, spanning the restriction enzyme sites used for  
subcloning (Fig. 1). A putative ribosome binding site could be identified  
(positions 782-785 of SEQ ID NO: 1). The ORF coded for 260 amino acids  
30 of a polypeptide of a molecular weight of 29,126 Da (SEQ ID NO: 2).

The amino acid sequence was found to contain a possible signal sequence of 27 amino acids. The sequence Leu-Val-Gly-Cys (positions 25 to 28 in SEQ ID NO: 2 and 4) is one of the consensus sequences (Leu-X-Y-Cys) assigned as a recognition site for the enzyme signal peptidase II. The signal peptidase II cleaves the signal sequences before the cysteine residue in prolipoproteins. The characteristics of the signal sequence thus suggest that the 29 kDa protein is a lipoprotein and that the mature protein comprises amino acids 28 to 260.

10     1.7. *Expression of the recombinant 29 kDa polypeptide in E. coli*

The recombinant 29 kDa polypeptide was produced in high concentration in *E. coli* N4830-1 from the expression vector construct pAL30, which contains the entire gene of the 29 kDa polypeptide (positions 771-1667 in SEQ ID NO: 1 and 3) The vector used for the construct was pML-LCTB  $\lambda$ 7 (obtained from Michael Lebens, University of Gothenburg, Sweden) which contains a strong  $\lambda P_L$  promoter. The vector also comprises a  $\beta$ -lactamase gene giving ampicillin resistance. The LCTB gene (encoding the cholera toxin and its signal peptide), which is inserted between the  $\lambda P_L$  promoter and a terminator region in the vector, was excised from the vector by cleaving with the restriction enzymes *Sma*I and *Hind*III.

The structural gene encoding the 29 kDa polypeptide, including its signal sequence, was amplified by Polymerase Chain Reaction (PCR). The primers used were HP30N (GGC GTA GAA ATG GAA GCG C; corresponding to positions 522 to 540 in SEQ ID NO: 1 and 3) which binds 271 bp upstream of the ATG start codon and HP30C (CCC AAG ATT CAT CAG CCC TTA AAT ACA CG) which recognizes a DNA fragment 855 bp downstream the start codon (corresponding to positions 1648 to 1667 in SEQ ID NO: 1 and 3). The HP30C primer contained a *Hind*III cleavage site which by the PCR reaction was added to the sequence of the 29 kDa polypeptide gene. The resulting PCR product was 1.1 kb. This DNA fragment was cleaved by *Ssp*I

-19-

and *HindIII* which gave a fragment of 0.9 kb which was ligated to the vector fragment (2.7 kb). The vector construct now called pAL30 (3.6 kb) was transformed into *E. coli* N4830-1 by electroporation. Four positive clones were found (pAL30:1, 2, 3, 4).

5

To induce expression of the recombinant polypeptide the N4830-1 cells containing the pAL30: 1 to 4 were grown over night at +30°C (the lambda cI repressor inhibits the transcription at this temperature) in 1 x LB with ampicillin (100 µg/ml). A small part of this over night culture was  
10 inoculated in 5 ml 1 x LB with ampicillin and the cells were grown at +30°C until the O.D. at 600 nm was about 0.7. The temperature was then raised to +42°C, whereby the repressor was inactivated, and incubated for two additional hours.

15

Samples taken before and after induction was analysed on 14% SDS-PAGE and by immunoblotting, using the monoclonal antibody HP30-1:1:6 which is specific for the 29 kDa polypeptide. All three induced clones used in immunoblotting (pAL30: 1, 3 and 4) expressed a large amount of the recombinant polypeptide after induction. The suspension from the non-  
20 induced cells contained only a low amount of the 29 kDa polypeptide.

The clone pAL30:1 was chosen for further analysis. In order to verify that the clone really contained the gene encoding the 29 kDa polypeptide, the ends of the fragment inserted in the vector was sequenced. It was verified  
25 that the sequence inserted into the expression vector corresponded to the expected sequence of the cloned PCR fragment.

EXAMPLE 2: Kinetics of expression of the 29 kDa polypeptide during  
30 various culture conditions

Two strains of *H. pylori* were used, namely CCUG 17874 (a laboratory strain) and Hel 73 (recently isolated from a patient suffering from duodenal ulcer). Cultivation was performed on blood agar plates, as well as in Brucella Broth supplemented with cyclodextrin. All cultures were incubated in a microaerophilic atmosphere consisting of 5% O<sub>2</sub>, 10% CO<sub>2</sub> and 85% N<sub>2</sub>. Bacteria were harvested after 2, 4 and 7 days, washed once in PBS and kept at -20°C for subsequent analysis. The expression of the 29 kDa surface polypeptide was analysed by inhibition-ELISA employing specific monoclonal antibodies as previously used for detection of *E. coli* surface antigens (Lopez-Vidal, Y and Svennerholm, A-M., J. Clin. Microbiol. 28, 1906-) against the polypeptide. These antibodies were also used in immunoelectron microscopy.

When CCUG 17874 had been cultivated for 7 days, on blood agar plates as well as in brucella broth, approximately 70% of the bacteria had converted from the spiral form to the coccoid form. This conversion occurred already after 3 days in Hel 73. The inhibition-ELISA showed a fairly constant concentration of the 29 kDa polypeptide in samples from both plate and broth cultures, during the 7 days. The presence of the polypeptide was confirmed by immunoelectron microscopy. The 29 kDa polypeptide was found to be well preserved in coccoid forms of *H. pylori*. The 29 kDa polypeptide was found to be more abundant in Hel 73 than in CCUG 17874.

25

### EXAMPLE 3: Antibody responses against the 29 kDa polypeptide

Antibody responses against the 29 kDa polypeptide were determined in sera and gastric aspirates from patients with duodenal ulcers (n=19), in asymptomatic *H. pylori* carriers (n=18) and in non-infected age-matched controls (n=20).

30

-21-

Antibody levels against the 29 kDa polypeptide were tested in gastric aspirates and in sera from the three groups of subjects, by means of different ELISA methods. A majority of the infected subjects had significantly higher levels, compared with the healthy control persons, of specific antibodies against the 29 kDa polypeptide both in serum and in gastric aspirates. Antibody titers in asymptomatic carriers were comparable to those of the symptomatic patients.

10      EXAMPLE 4: Labelling of polypeptides with [<sup>3</sup>H]palmitate

Since the amino acid sequence of the 29 kDa polypeptide contained a possible signal peptide typical for lipoproteins, the labelling of the protein with radioactive palmitic acid was investigated:

15      *E. coli* N4830-1, either lacking or carrying pAL30:1, were grown at +30°C in LB-broth supplemented with 50 µg of carbencillin / ml. At a cell density of 10<sup>8</sup> bacteria / ml, [<sup>3</sup>H]palmitic acid (5 mCi/ml; DuPont NEN, Boston, MA) was added to a final concentration of 50 µCi/ml. The temperature was raised to +42°C and the cultures were incubated for another 12 h. The cells were collected by centrifugation and lysed in SDS-PAGE lysis buffer. After electrophoresis, the gel was processed for fluorography by immersing the gel in Amplify™ (Amersham International, UK) for 30 min, drying it between cellophane sheets and exposing the gel to X-ray film at -70°C for 36 h.

25      The results indicated that the 29 kDa polypeptide is lipidated and thus post-translationally modified.



-22-

EXAMPLE 5: Triton X-114 partitioning of *E. coli* expressing the recombinant 29 kDa polypeptide

*E. coli* cells carrying pAL30:1 were grown at +30°C in LB-broth  
5 supplemented with 50 µg carbencillin / ml. At a cell density of  $10^8$   
bacteria / ml, the temperature was raised to +42°C and the cultures were  
incubated for another 3 h. The cells were collected by centrifugation ( $11.300 \times g$ , 10 min, +4°C) and resuspended in 25 ml of PBS per gram of cell pellet.  
The suspension was frozen and then thawed at room temperature, and 25  
10 µl DNase I (10 µg/µl) was added. The sample was gently shaken by  
inversion for 30 min at room temperature and chilled to 8-12°C followed  
by the addition of Triton X-114 (final concentration 0.3%). After incubation  
by gentle inversion at +4°C for 3 h the insoluble material was collected by  
centrifugation ( $18.900 \times g$ , 10 min, +25°C).

15

The phases were analysed by SDS-PAGE and the identity of the 29 kDa  
polypeptide was verified by Western blotting using MAb HP30-1:1:6. The  
results indicated that the 29 kDa polypeptide appeared in the detergent  
phase, which confirmed that it is a lipoprotein. It is known in the art that  
20 integral membrane proteins are normally recovered in the detergent phase  
(Bordier, C. (1981) J. Biol. Chem., vol. 256, 1604-1607).

-----  
This experiment also verified that a plasmid inserted into *E. coli* could  
express and produce the 29 kDa protein. This is important for the future  
25 production of a vaccine in larger scale, since *H. pylori* does not grow very  
well or fast.

EXAMPLE 6: Construction of expression vector pS863 for production of  
30 high levels of *H. pylori* 29 kDa protein

### 6.1. Preparation of pS860

To generate convenient restriction sites for the 5'-end of the 29 kDa gene, two synthetic oligonucleotides for PCR amplification were synthesized. The plasmid pS852 (identical to the plasmid pAL30:1 described in Example 1.7) was used as a template for the PCR amplification. The sequences of these two oligonucleotides are listed below:

*EcoRI NdeI*  
 5'-CGGAATTCCATATGAGAGCAAATAATCATTTTAAAG-3'

*BamHI XmaI NheI*  
 5'-GCGGATCCCCGGGGCTAGCTGGATGGTAATTC AATTTTC-3'

PCR amplification was performed and the 169 bp amplified fragment was ligated into the TA vector (Mead, D.A. et al. (1991) *Bio/Technology* 9, 657-663). The constructed plasmid was designated pS860 (Fig. 2). The sequence of the construct was confirmed by dideoxy sequencing (Sanger et al. (1977) *Proc. Natl. Acad. Sci. USA* 74, 5463-5467).

### 6.2. Preparation of pS861

In order to change restriction sites in the 3'-end of the 29 kDa gene two synthetic oligonucleotides for PCR amplification were synthesized. The plasmid pS852 (pAL30:1) was used as a template for the PCR amplification. The sequences of the two oligonucleotides are listed below:

*EcoRI XmaI*  
 5'-CGGAATTC CCGGGTTATTATTCTCCACCGG-3'

*PstI BamHI*  
 5'-CGCTGCAGGGATCCTTATTATCGGTTTCTTTTGCCTTTTAA-3'

PCR amplification were performed and the amplified fragment was digested with *XmaI* and *BamHI* generating a 357 bp fragment. This fragment was cloned into pUC19, the constructed plasmid was designated

pS861 (Fig. 2). The sequence of the construct was confirmed by dideoxy sequencing (Sanger et al. (1977) Proc. Natl. Acad. Sci. USA 74, 5463-5467).

### 6.3. Preparation of plasmid pS862

5

The cDNA encoding the middle part of the 29 kDa gene was isolated by gel electrophoresis as a 280 bp *NheI/XmaI* fragment from the plasmid pS852 (pAL30:1). This fragment was ligated together with a 357 bp *XmaI/BamHI* fragment from pS861 and a 4061 bp *NheI/BamHI* fragment from pS861. The generated plasmid was designated pS862 (Fig. 2).

### 6.4. Preparation of plasmid pS863

Thereafter, a 795 bp *NdeI* and *BamHI* restriction fragment was isolated from pS862 and ligated to a 4 kb *NdeI/BamHI* fragment from T7 vector pS637(pET-3a) (Studier, F.W. et al. (1990) Methods Enzymol. 185, 60-89). The resulting expression vector was designated pS863 (Fig. 2).

## 20 EXAMPLE 7: Purification of recombinant *H. pylori* 29 kDa lipoprotein

### 7.1. Host strains and bacterial cultures

The expression vector pS863 was transformed into the following *E.coli* host strains; BL21(DE3); BL21(DE3)pLysS; and BL21(DE3)pLysE. The expression experiments were carried out essentially as described by Studier et al. (Methods Enzymol. 185, 60-89, 1990). The bacteria were grown in LB medium (Ausubel, F.M. et al. (eds.) Current Protocols in Molecular Biology, John Wiley & Sons, New York, 1992) containing 50 µg/ml carbencillin. In addition, when BL21(DE3)pLysS and BL21(DE3)pLysE were used, the medium was supplemented with 30 µg/ml chloramphenicol. For

-25-

induction of the T7 expression system, the cultures were grown to a density of approximately  $OD_{600} = 0.5$ , and then supplemented with 0.4 mM IPTG for induction. The cells were harvested about 180 minutes after induction. The host strain that gave the highest expression level was

5 BL21(DE3)pLysS.

## 7.2. Purification of the *H. pylori* 29 kDa lipoprotein

Cultures of *E. coli* BL21(DE3)/pLysS transformed with plasmid pS863 were

10 grown as described above and the cells were collected by centrifugation and resuspended in cold buffer (50 mM Tris-HCl, 2 mM EDTA, 10 mM NaCl, pH 8.0). For each gram of pellet (wet weight) 35 ml of buffer was added.

### 15 7.2.1. Triton X-114 extraction

To extract the lipoprotein, Triton X-114 (TX-114) was added to a final concentration of 1.5% (v/v) and the suspension was stirred for one hour at 0°C. The Triton-insoluble material was pelleted by centrifugation at 18,900

20 x g for 10 min. In some cases the pellet was extracted once more but with half the volume of TX-114 containing buffer. After the second TX-114 extraction the pellet was discarded.

Phase partitioning of the supernatant from the TX-114 extraction was

25 obtained by incubating it for 15 min at +30°C with occasional mixing. The turbid solution was centrifuged at 31,300 x g for 30 min at +30°C. The lower detergent phase was collected and diluted to 1% TX-114 with cold buffer (50 mM Tris-HCl, 2 mM EDTA, 10 mM NaCl, pH 8.0).

### 7.2.2. *Q-sepharose, pH 8.0*

The diluted TX-114-phase was applied to a Q-sepharose column (Pharmacia) (20 ml/3 g cell pellet) equilibrated with buffer (50 mM Tris-HCl, 2 mM EDTA, 10 mM NaCl, 0.1% Triton X-100, pH 8.0). The 29 kDa lipoprotein was collected as the non-binding fraction. This fraction was phase partitioned by incubating it at +30°C with occasional mixing until the solution was turbid. The two phases were separated by centrifugation at 31,300 x g for 30 min at +30°C. The lower detergent phase was collected and diluted to 1% TX-114 with cold buffer (10 mM Tris-HCl, 2 mM EDTA, pH 8.6).

### 7.2.3. *Q-sepharose, pH 8.6*

The diluted TX-114-phase was applied to a 100 ml Q-sepharose column (Pharmacia) equilibrated with buffer (10 mM Tris-HCl, 2 mM EDTA, pH 8.6). The non-binding fraction contained TX-114. The column was washed with buffer A (10 mM Tris-HCl, 2 mM EDTA, 0.1% Triton X-100, pH 8.6). The 29 kDa lipoprotein was collected by a salt gradient with buffer B (10 mM Tris-HCl, 2 mM EDTA, 0.1% Triton X-100, 1 M NaCl, pH 8.6). The gradient was as follows; 0-50%B, 40 ml; 50-100%B, 100 ml. The 29 kDa lipoprotein eluted between 60-70% B.

### 7.2.4. *SDS-PAGE and protein electrophoretic blotting*

25

Protein samples from the different purification steps were solubilized in sample buffer (50 mM Tris-HCl, pH 6.8, 8% glycerol, 1.6% SDS, 4%  $\beta$ -mercaptoethanol, 0.02% bromophenol blue) and separated on Novex precast gradient gels (4-20% polyacrylamide) or BioRad precast gradient gels (10-20% polyacrylamide). The electrophoresis running buffer contained 25 mM

-27-

Tris, 192 mM glycine, 0.5% SDS, pH 8.3. Gels were stained with 0.1% Coomassie Brilliant Blue R-250 in 40% methanol, 10% acetic acid and destained with 10% methanol, 10% acetic acid.

- 5 Gels intended for Semi-Dry-electroblotting were not stained but soaked in Transfer buffer (48 mM Tris, 38 mM glycine, 0.075 % SDS, 20 % MeOH) and proteins were transferred onto PVDF membranes (Immobilon<sup>®</sup>, Millipore, USA) by a SemiDry electroblotting apparatus (BioRad). Immunodetection was accomplished by first blocking the PVDF membrane for one hour in 10 2% BSA in TBS (50 mM Tris-HCl, 2.5 M NaCl, pH 8.2) and thereafter the membrane was incubated for one hour with a specific monoclonal antibody (IgG1) against the 29 kDa lipoprotein diluted 1:10 with 1% BSA in TBS. After a washing step with TBS the membrane was incubated for one hour with an alkaline phosphatase-conjugated anti-mouse IgG antibody 15 (Dakopatts, Denmark). After an additional wash the membrane was developed with appropriate substrates (5-bromo-4-chloro-3-indolyl phosphate (BCIP) and nitroblue tetrazolium (NBT) (Sigma)).

#### 7.2.5. Protein concentration and pyrogenicity

20

Total protein concentration was determined by the bicinchoninic acid method (BCA Protein Assay. Pierce Chemical Company, USA).

- 25 The endotoxin content was assayed by a chromogenic *Limulus* amoebocyte lysate (LAL) test (LAL COAMATIC<sup>®</sup> Endotoxin. Endosafe Inc. USA)

Stained SDS-gels were scanned (BioRad Imager GS-) to determine the relative amount of protein contaminants in the final preparations. The preparations contained < 10% protein contaminants.

30

EXAMPLE 8: Analysis of the *H. pylori* 29 kDa protein for use as a vaccine

## 8.1. Materials &amp; Methods

## 5 8.1.1. Animals

Female SPF BALB/c mice were purchased from Bomholt Breeding centre (Denmark). They were kept in ordinary makrolon cages with free supply of water and food. The animals were 4-6 weeks old at arrival.

10

## 8.1.2. Infection

After a minimum of one week of acclimatization, the animals were infected with a type 2 strain of *H. pylori* (strain 244, originally isolated from an ulcer patient). This strain has earlier proven to be a good colonizer of the mouse stomach. The bacteria were grown overnight in Brucella broth supplemented with 10% fetal calf serum, at +37°C in a microaerophilic atmosphere (10% CO<sub>2</sub>, 5% O<sub>2</sub>). The animals were given an oral dose of omeprazole (400 mmol/kg) and after 3-5 h an oral inoculation of *H. pylori* (approximately 10<sup>8</sup> cfu/animal). Infection was checked in control animals 2-3 weeks after the inoculation.

20

## 8.1.3. Immunizations

25 The animals were immunized 4 times over a 34 day period (day 1, 15, 25 and 35). Purified antigen was given at a dose of 100 µg/mouse and membrane proteins (MP) at a dose of 0.5 mg/dose. Membrane proteins were prepared by sonication of bacteria in PBS. Debris was removed by spinning the sonicate at +4°C, 2000 rpm for 5 min. The supernatant was

-29-

transferred to a new tube and spun at +4°C, 15,000 rpm for 20 min. The pellet was recovered and stored at -70°C until use.

5 As an adjuvant, the animals were also given 10 µg/mouse of cholera toxin (CT) with each immunization. Omeprazole (400 µmol/kg) was given orally to the animals 3-5 h prior to immunization as a way of protecting the antigens from acid degradation. Animals were sacrificed 4 weeks after final immunization.

10 8.1.4. *Passive protection*

To analyze the effect of monoclonal antibodies (MAbs) on the ability of *H. pylori* to colonize the mouse stomach, MAbs with different specificities were mixed with *H. pylori* 10 min prior to inoculation as described above.  
15 MAbs raised against the 29 kDa protein (HP30-1:1:6), against urease (Ure 8:1); and against the *E. coli* heat-stable protein (ST 1:3) were used. The MAbs were titrated in an ELISA to allow for equal amounts of each MAb to be used in the experiment. A number of  $10^7$  bacteria per mouse were used for inoculation. The mice were sacrificed 2 weeks post inoculation.

20

— 8.1.5. *Analysis of infection*

The mice were sacrificed by CO<sub>2</sub> and cervical dislocation. The abdomen was opened and the stomach removed. After cutting the stomach along the greater curvature, it was rinsed in saline. The mucosa from the antrum and  
25 corpus of an area of 25 mm<sup>2</sup> was scraped separately with a surgical scalpel. The mucosa scraping was suspended in Brucella broth and plated onto Blood Skirrow plates. The plates were incubated under microaerophilic conditions for 3-5 days and the number of colonies was  
30 counted. The identity of *H. pylori* was ascertained by urease and catalase test and by direct microscopy or Gram staining.



## 8.2. Results

### 8.2.1 Passive protection

5        Three groups with 10 animals in each were given a mixture of *H. pylori*  
strain 244 and a MAb, and one group was given only *H. pylori*. The  
mixture of MAb and bacteria was allowed to react for 10 min before being  
inoculated into the mice. None of the MAbs used had any clear effect on  
the bacteria *in vitro*. Two weeks after inoculation, the mice were sacrificed  
10        and the infection rate was determined for each group (Fig. 3). All of the  
mice in the control group and those inoculated with the ST Mab were  
infected. In the urease MAb group all mice were infected, but to a  
significantly lower degree compared with the controls. In the group  
inoculated with the MAb against the 29 kDa protein, none of the mice  
15        were infected.

### 8.2.2. Therapeutic immunization

The animals in this study were infected with *H. pylori* strain 244 one month  
20        prior to immunizations. Mice in groups of ten were then immunized with  
either cholera toxin (CT) or CT together with membrane proteins, urease or  
the 29 kDa protein. Control animals received vehicle only (PBS). One  
month after the final immunization, the animals were sacrificed and CFU  
was determined (Fig. 4). All control animals, as well as those immunized  
25        with only CT, were infected. Animals actively immunized with urease and  
CT, or with 29 kDa protein and CT, had significantly decreased CFU  
values compared with the controls. Only one animal in the urease-  
immunized group was completely cured from the infection.

### 8.3. Conclusions

The results above indicate that the 29 kDa *H. pylori* protein is important for the colonization and/or persistence of an infection, since binding of a MAb  
5 to this structure result in complete inhibition of colonisation.

Furthermore, the 29 kDa *H. pylori* protein, when used as an oral immunogen in conjunction with cholera toxin as an oral adjuvant, acts as a stimulator of an immune response leading to a significant reduction of the  
10 degree of colonisation of *H. pylori* in the used animal model.

Taken together, these results strongly support the use of the 29 kDa *H. pylori* protein in an oral vaccine formulation for the use in humans to treat and prevent *H. pylori* infections.  
15

### DEPOSIT OF MICROORGANISMS

The plasmid pAE1 has been deposited under the Budapest Treaty at the  
20 National Collections of Industrial and Marine Bacteria (NCIMB), Aberdeen, Scotland, UK, and under accession number NCIMB 40732. The date of deposit is 16 May 1995.

-32-

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

## (i) APPLICANT:

(A) NAME: ASTRA AB  
(B) STREET: Västra Mälarehamnen 9  
(C) CITY: Södertälje  
(E) COUNTRY: Sweden  
(F) POSTAL CODE (ZIP): S-151 85  
(G) TELEPHONE: +46 8 553 260 00  
(H) TELEFAX: +46 8 553 288 20  
(I) TELEX: 19237 astra s

(ii) TITLE OF INVENTION: Bacterial Antigens and Vaccine Compositions

(iii) NUMBER OF SEQUENCES: 4

## (iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

## (2) INFORMATION FOR SEQ ID NO: 1:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1670 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (ix) FEATURE:

(A) NAME/KEY: CDS  
(B) LOCATION: 793..1575

## (ix) FEATURE:

(A) NAME/KEY: mat\_peptide  
(B) LOCATION: 793..1572

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

GATCCTATCG CGCCAAAGGT GGTATTAGGA ATAAGAGCTT GATTATTAAT CTCCCTGGTA	60
AGTCCAAAAA GTATTAGAGA ATGCTTAGAG GCGGTTTTTC CAGCGATTCC TTATTGCGTG	120
GATTTGATTT TAGGGAATTA CATGCAAGTG AATGAAAAAA ACATTCAAGC GTTTGCCCCC	180
AAACAATAAG GTAAAAAATG CCACTCACTC ATTTGAATGA AGAAATCAA CCTAAAATGG	240
TGGATATAGG GGATAAAGAA ACCACTGAAA GAATCGCTCT AGCAAGCGGT CGTATCAGCA	300

-33-

TGAATAAAGA GGCTTATGAC GCTATTATCA ATCATGGCGT CAAAAAGGGT CCGGTATTAC	360
AAACTGCTAT TATTGCTGGG ATTATGGGGG CTAAAAAGAC AAGCGAACTC ATTCCCATGT	420
GCCATCCAAT CATGCTCAAT GGGGTGGATA TTGATATTTT AGAAGAAAAA GAGACTTGTA	480
GTTTTAAACT CTATGCGAGA GTCAAAACTC AAGCTAAAAC GGGCGTAGAA ATGGAAGCGC	540
TAATGAGTGT GAGCGTAGGG CTTTTAACCA TTTATGACAT GGTGAAAGCC ATTGATAAGA	600
GCATGACAAT TAGCGGTGTG ATGCTGGAAT ATAAAAGTGG AGGCAAAAGT GGGGATTATA	660
ACGCTAAAAA ATAGAAAAAG ACTGATAATC TAAAGATATT AGGGTAAAAA AACATTTTGA	720
CAACAAAAGC GTGTTGGTTG CTTCCGATTT GTTGTATAG AAGTCTAAAA TATTACAATC	780
AAGGATAGAA CG ATG AGA GCA AAT AAT CAT TTT AAA GAT TTT GCA TGG	828
Met Arg Ala Asn Asn His Phe Lys Asp Phe Ala Trp	
1 5 10	
AAA AAA TGC CTT TTA GGC GCG AGC GTG GTG GCT TTA TTA GTG GGA TGC	876
Lys Lys Cys Leu Leu Gly Ala Ser Val Val Ala Leu Leu Val Gly Cys	
15 20 25	
AGC CCG CAT ATT ATT GAA ACC AAT GAA GTC GCT TTG AAA TTG AAT TAC	924
Ser Pro His Ile Ile Glu Thr Asn Glu Val Ala Leu Lys Leu Asn Tyr	
30 35 40	
CAT CCA GCT AGC GAG AAA GTT CAA GCG TTA GAT GAA AAG ATT TTG CTT	972
His Pro Ala Ser Glu Lys Val Gln Ala Leu Asp Glu Lys Ile Leu Leu	
45 50 55 60	
TTA AGG CCA GCT TTC CAA TAT AGC GAT AAT ATC GCT AAA GAG TAT GAA	1020
Leu Arg Pro Ala Phe Gln Tyr Ser Asp Asn Ile Ala Lys Glu Tyr Glu	
65 70 75	
AAC AAA TTC AAG AAT CAA ACC GCG CTC AAG GTT GAA CAG ATT TTG CAA	1068
Asn Lys Phe Lys Asn Gln Thr Ala Leu Lys Val Glu Gln Ile Leu Gln	
80 85 90	
AAT CAA GGC TAT AAG GTT ATT AGC GTA GAT AGC AGC GAT AAA GAC GAT	1116
Asn Gln Gly Tyr Lys Val Ile Ser Val Asp Ser Ser Asp Lys Asp Asp	
95 100 105	
TTT TCT TTT GCA CAA AAA AAA GAA GGG TAT TTG GCG GTT GCT ATG AAT	1164
Phe Ser Phe Ala Gln Lys Lys Glu Gly Tyr Leu Ala Val Ala Met Asn	
110 115 120	
GGC GAA ATT GTT TTA CGC CCC GAT CCT AAA AGG ACC ATA CAG AAA AAA	1212
Gly Glu Ile Val Leu Arg Pro Asp Pro Lys Arg Thr Ile Gln Lys Lys	
125 130 135 140	
TCA GAA CCC GGG TTA TTA TTC TCC ACC GGT TTG GAC AAA ATG GAA GGG	1260
Ser Glu Pro Gly Leu Leu Phe Ser Thr Gly Leu Asp Lys Met Glu Gly	
145 150 155	

-34-

GTT TTA ATC CCG GCT GGG TTT ATT AAG GTT ACC ATA CTA GAG CCT ATG Val Leu Ile Pro Ala Gly Phe Ile Lys Val Thr Ile Leu Glu Pro Met 160 165 170	1308
AGT GGG GAA TCT TTG GAT TCT TTT ACG ATG GAT TTG AGC GAG TTG GAC Ser Gly Glu Ser Leu Asp Ser Phe Thr Met Asp Leu Ser Glu Leu Asp 175 180 185	1356
ATT CAA GAA AAA TTC TTA AAA ACC ACC CAT TCA AGC CAT AGC GGG GGG Ile Gln Glu Lys Phe Leu Lys Thr Thr His Ser Ser His Ser Gly Gly 190 195 200	1404
TTA GTT AGC ACT ATG GTT AAG GGA ACG GAT AAT TCT AAT GAC GCG ATC Leu Val Ser Thr Met Val Lys Gly Thr Asp Asn Ser Asn Asp Ala Ile 205 210 215 220	1452
AAG AGC GCT TTG AAT AAG ATT TTT GCA AAT ATC ATG CAA GAA ATA GAC Lys Ser Ala Leu Asn Lys Ile Phe Ala Asn Ile Met Gln Glu Ile Asp 225 230 235	1500
AAA AAA CTC ACT CAA AAG AAT TTA GAA TCT TAT CAA AAA GAC GCC AAA Lys Lys Leu Thr Gln Lys Asn Leu Glu Ser Tyr Gln Lys Asp Ala Lys 240 245 250	1548
GAA TTA AAA GGC AAA AGA AAC CGA TAA AAACAAATAA CGCATAAGAA Glu Leu Lys Gly Lys Arg Asn Arg 255 260	1595
AAGAACGCTT GAATAAACTG CTTAAAAAGG GTTTTTTAGC GTTCTTTTTC AGCGTGTATT	1655
TAAGGGCTGA TGATC	1670

## (2) INFORMATION FOR SEQ ID NO: 2:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 261 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Met Arg Ala Asn Asn His Phe Lys Asp Phe Ala Trp Lys Lys Cys Leu 1 5 10 15
Leu Gly Ala Ser Val Val Ala Leu Leu Val Gly Cys Ser Pro His Ile 20 25 30
Ile Glu Thr Asn Glu Val Ala Leu Lys Leu Asn Tyr His Pro Ala Ser 35 40 45
Glu Lys Val Gln Ala Leu Asp Glu Lys Ile Leu Leu Leu Arg Pro Ala 50 55 60
Phe Gln Tyr Ser Asp Asn Ile Ala Lys Glu Tyr Glu Asn Lys Phe Lys 65 70 75 80

-35-

Asn Gln Thr Ala Leu Lys Val Glu Gln Ile Leu Gln Asn Gln Gly Tyr  
                             85                            90                            95  
 Lys Val Ile Ser Val Asp Ser Ser Asp Lys Asp Asp Phe Ser Phe Ala  
                             100                            105                            110  
 Gln Lys Lys Glu Gly Tyr Leu Ala Val Ala Met Asn Gly Glu Ile Val  
                             115                            120                            125  
 Leu Arg Pro Asp Pro Lys Arg Thr Ile Gln Lys Lys Ser Glu Pro Gly  
                             130                            135                            140  
 Leu Leu Phe Ser Thr Gly Leu Asp Lys Met Glu Gly Val Leu Ile Pro  
                             145                            150                            155                            160  
 Ala Gly Phe Ile Lys Val Thr Ile Leu Glu Pro Met Ser Gly Glu Ser  
                             165                            170                            175  
 Leu Asp Ser Phe Thr Met Asp Leu Ser Glu Leu Asp Ile Gln Glu Lys  
                             180                            185                            190  
 Phe Leu Lys Thr Thr His Ser Ser His Ser Gly Gly Leu Val Ser Thr  
                             195                            200                            205  
 Met Val Lys Gly Thr Asp Asn Ser Asn Asp Ala Ile Lys Ser Ala Leu  
                             210                            215                            220  
 Asn Lys Ile Phe Ala Asn Ile Met Gln Glu Ile Asp Lys Lys Leu Thr  
                             225                            230                            235                            240  
 Gln Lys Asn Leu Glu Ser Tyr Gln Lys Asp Ala Lys Glu Leu Lys Gly  
                             245                            250                            255  
 Lys Arg Asn Arg \*  
                             260

## (2) INFORMATION FOR SEQ ID NO: 3:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1670 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 793..1575

## (ix) FEATURE:

- (A) NAME/KEY: mat\_peptide
- (B) LOCATION: 793..1572

-36-

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

GATCCTATCG CGCCAAAGGT GGTATTAGGA ATAAGAGCTT GATTATTAAT CTCCTGGTA	60
AGTCCAAAAA GTATTAGAGA ATGCTTAGAG GCGGTTTTTC CAGCGATTCC TTATTGCGTG	120
GATTTGATTT TAGGGAATTA CATGCAAGTG AATGAAAAAA ACATTCAAGC GTTTGCCCCC	180
AAACAATAAG GTAAAAATG CCACTCACTC ATTTGAATGA AGAAAATCAA CCTAAAATGG	240
TGGATATAGG GGATAAAGAA ACCACTGAAA GAATCGCTCT AGCAAGCGGT CGTATCAGCA	300
TGAATAAAGA GGCTTATGAC GCTATTATCA ATCATGGCGT CAAAAAGGGT CCGGTATTAC	360
AAACTGCTAT TATTGCTGGG ATTATGGGGG CTAAAAAGAC AAGCGAACTC ATTCCCATGT	420
GCCATCCAAT CATGCTCAAT GGGGTGGATA TTGATATTTT AGAAGAAAAA GAGACTTGTA	480
GTTTTAAACT CTATGCGAGA GTCAAAACTC AAGCTAAAC GGGCGTAGAA ATGGAAGCGC	540
TAATGAGTGT GAGCGTAGGG CTMTTAACCA TTTATGACAT GGTGAAAGCC ATTGATAAGA	600
GCATGACAAT TAGCGGTGTG ATGCTGGAAT ATAAAAGTGG AGGCAAAAGT GGGGATTATA	660
ACGCTAAAAA ATAGAAAAAG ACTGATAATC TAAAGATATT AGGGTAAAAT AACATTTTGA	720
CAACAAAAGC GTGTTGGTTG CTTCGGATTT GTTGTATAG AAGTCTAAAA TATTACAATC	780
AAGGATAGAA CG ATG AGA GCA AAT AAT CAT TTT AAA GAT TTT GCA TGG	828
Met Arg Ala Asn Asn His Phe Lys Asp Phe Ala Trp	
1 5 10	
AAA AAA TGC CTT TTA GGC GCG AGC GTG GTG GCT TTA TTA GTG GGA TGC	876
Lys Lys Cys Leu Leu Gly Ala Ser Val Val Ala Leu Leu Val Gly Cys	
15 20 25	
AGC CCG CAT ATT ATT GAA ACC AAT GAA GTC GCT TTG AAA TTG AAT TAC	924
Ser Pro His Ile Ile Glu Thr Asn Glu Val Ala Leu Lys Leu Asn Tyr	
30 35 40	
CAT CCA GCT AGC GAG AAA GTT CAA GCG TTA GAT GAA AAG ATT TTG CTT	972
His Pro Ala Ser Glu Lys Val Gln Ala Leu Asp Glu Lys Ile Leu Leu	
45 50 55 60	
TTA AGG CCA GCT TTC CAA TAT AGC GAT AAT ATC GCT AAA GAG TAT GAA	1020
Leu Arg Pro Ala Phe Gln Tyr Ser Asp Asn Ile Ala Lys Glu Tyr Glu	
65 70 75	
AAC AAA TTC AAG AAT CAA ACC GCG CTC AAG GTT GAA CAG ATT TTG CAA	1068
Asn Lys Phe Lys Asn Gln Thr Ala Leu Lys Val Glu Gln Ile Leu Gln	
80 85 90	
AAT CAA GGC TAT AAG GTT ATT AGC GTA GAT AGC AGC GAT AAA GAC GAT	1116
Asn Gln Gly Tyr Lys Val Ile Ser Val Asp Ser Ser Asp Lys Asp Asp	
95 100 105	

-37-

TTT TCT TTT GCA CAA AAA AAA GAA GGG TAT TTG GCG GTT GCT ATG AAT Phe Ser Phe Ala Gln Lys Lys Glu Gly Tyr Leu Ala Val Ala Met Asn 110 115 120	1164
GGC GAA ATT GTT TTA CGC CCC GAT CCT AAA AGG ACC ATA CAG AAA AAA Gly Glu Ile Val Leu Arg Pro Asp Pro Lys Arg Thr Ile Gln Lys Lys 125 130 135 140	1212
TCA GAA CCC GGG TTA TTA TTC TCC ACC GGT TTG GAC AAA ATG GAA GGG Ser Glu Pro Gly Leu Leu Phe Ser Thr Gly Leu Asp Lys Met Glu Gly 145 150 155	1260
GTT TTA ATC CCG GCT GGG TTT ATT AAG GTT ACC ATA CTA GAG CCT ATG Val Leu Ile Pro Ala Gly Phe Ile Lys Val Thr Ile Leu Glu Pro Met 160 165 170	1308
AGT GGG GAA TCT TTG GAT TCT TTT ACG ATG GAT TTG AGC GAG TTG GAC Ser Gly Glu Ser Leu Asp Ser Phe Thr Met Asp Leu Ser Glu Leu Asp 175 180 185	1356
ATT CAA GAA AAA TTC TTA AAA ACC ACC CAT TCA AGC CAT AGC GGG GGG Ile Gln Glu Lys Phe Leu Lys Thr Thr His Ser Ser His Ser Gly Gly 190 195 200	1404
TTA GTT AGC ACT ATG GTT AAG GGA ACG GAT AAT TCT AAT GAC GCG ATC Leu Val Ser Thr Met Val Lys Gly Thr Asp Asn Ser Asn Asp Ala Ile 205 210 215 220	1452
AAG AGA GCT TTG AAT AAG ATT TTT GCA AAT ATC ATG CAA GAA ATA GAC Lys Arg Ala Leu Asn Lys Ile Phe Ala Asn Ile Met Gln Glu Ile Asp 225 230 235	1500
AAA AAA CTC ACT CAA AAG AAT TTA GAA TCT TAT CAA AAA GAC GCC AAA Lys Lys Leu Thr Gln Lys Asn Leu Glu Ser Tyr Gln Lys Asp Ala Lys 240 245 250	1548
GAA TTA AAA GGC AAA AGA AAC CGA TAA AAACAAATAA CGCATAAGAA Glu Leu Lys Gly Lys Arg Asn Arg * 255 260	1595
AAGAACGCTT GAATAAACTG CTTAAAAAGG GTTTTTTAGC GTTCTTTTIG ACCGTGTATT TAAGGGCTGA TGATC	1655 1670

## (2) INFORMATION FOR SEQ ID NO: 4:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 261 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Met Arg Ala Asn Asn His Phe Lys Asp Phe Ala Trp Lys Lys Cys Leu  
1 5 10 15



-38-

Leu Gly Ala Ser Val Val Ala Leu Leu Val Gly Cys Ser Pro His Ile  
                   20                  25                  30  
 Ile Glu Thr Asn Glu Val Ala Leu Lys Leu Asn Tyr His Pro Ala Ser  
                   35                  40                  45  
 Glu Lys Val Gln Ala Leu Asp Glu Lys Ile Leu Leu Leu Arg Pro Ala  
                   50                  55                  60  
 Phe Gln Tyr Ser Asp Asn Ile Ala Lys Glu Tyr Glu Asn Lys Phe Lys  
                   65                  70                  75                  80  
 Asn Gln Thr Ala Leu Lys Val Glu Gln Ile Leu Gln Asn Gln Gly Tyr  
                   85                  90                  95  
 Lys Val Ile Ser Val Asp Ser Ser Asp Lys Asp Asp Phe Ser Phe Ala  
                   100                  105                  110  
 Gln Lys Lys Glu Gly Tyr Leu Ala Val Ala Met Asn Gly Glu Ile Val  
                   115                  120                  125  
 Leu Arg Pro Asp Pro Lys Arg Thr Ile Gln Lys Lys Ser Glu Pro Gly  
                   130                  135                  140  
 Leu Leu Phe Ser Thr Gly Leu Asp Lys Met Glu Gly Val Leu Ile Pro  
                   145                  150                  155                  160  
 Ala Gly Phe Ile Lys Val Thr Ile Leu Glu Pro Met Ser Gly Glu Ser  
                   165                  170                  175  
 Leu Asp Ser Phe Thr Met Asp Leu Ser Glu Leu Asp Ile Gln Glu Lys  
                   180                  185                  190  
 Phe Leu Lys Thr Thr His Ser Ser His Ser Gly Gly Leu Val Ser Thr  
                   195                  200                  205  
 Met Val Lys Gly Thr Asp Asn Ser Asn Asp Ala Ile Lys Arg Ala Leu  
                   210                  215                  220  
 Asn Lys Ile Phe Ala Asn Ile Met Gln Glu Ile Asp Lys Lys Leu Thr  
                   225                  230                  235                  240  
 Gln Lys Asn Leu Glu Ser Tyr Gln Lys Asp Ala Lys Glu Leu Lys Gly  
                   245                  250                  255  
 Lys Arg Asn Arg \*  
                   260

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

<b>A.</b> The indications made below relate to the microorganism referred to in the description on page <u>30</u> , line <u>17-22</u>	
<b>B. IDENTIFICATION OF DEPOSIT</b> <span style="float: right;">Further deposits are identified on an additional sheet <input type="checkbox"/></span>	
Name of depositary institution <p style="text-align: center;">The National Collections of Industrial and Marine Bacteria Limited (NCIMB)</p>	
Address of depositary institution (including postal code and country) <p style="text-align: center;">23 St Machar Drive          Aberdeen AB2 1RY          Scotland, UK</p>	
Date of deposit <p style="text-align: center;">16 May 1995</p>	Accession Number <p style="text-align: center;">NCIMB 40732</p>
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable) <span style="float: right;">This information is continued on an additional sheet <input type="checkbox"/></span>	
<p>In respect of all designated states in which such action is possible and to the extent that it is legally permissible under the law of the designated state, it is requested that a sample of the deposited micro-organism be made available only by the issue thereof to an independent expert, in accordance with the relevant patent legislation, e.g. Rule 28(4) EPC, and generally similar provisions <i>mutatis mutandis</i> for any other designated state.</p>	
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)	
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<p style="text-align: center;"><b>For receiving Office use only</b></p> <p><input checked="" type="checkbox"/> This sheet was received with the international application</p> <hr/> Authorized officer <p style="text-align: center;"><i>Marisa J. ...</i></p>	<p style="text-align: center;"><b>For International Bureau use only</b></p> <p><input type="checkbox"/> This sheet was received by the International Bureau on:</p> <hr/> Authorized officer
---	--

## CLAIMS

1. A recombinant polypeptide which has an amino acid sequence identical with, or substantially similar to, a *Helicobacter pylori* surface-exposed antigen with an approximate molecular weight of 29 kDa.  
5
2. A polypeptide according to claim 1 which amino acid sequence is identical with, or substantially similar to, positions 1-260 or 28-260 in SEQ ID NO: 2 or SEQ ID NO: 4 in the Sequence Listing.  
10
3. A peptide with a length of at least 5 amino acids comprising an immunogenic epitope of a polypeptide according to claim 1.
4. An isolated nucleic acid molecule which has a nucleotide sequence coding for a polypeptide according to claim 1 or 2.  
15
5. An isolated nucleic acid molecule selected from:  
(a) nucleic acid molecules comprising a nucleotide sequence which is identical with, or substantially similar to, positions 796-1572 or 874-1572 in SEQ ID NO: 1 or SEQ ID NO: 3 in the Sequence Listing;  
20  
(b) nucleic acid molecules comprising a nucleotide sequence capable of hybridizing to a nucleotide sequence complementary to the polypeptide coding region of a nucleic acid molecule as defined in (a) and which codes for a polypeptide according to claim 1 or 2, or a functionally equivalent modified form thereof; and  
25  
(c) nucleic acid molecules comprising a nucleic acid sequence which is degenerate as a result of the genetic code to a nucleotide sequence as defined in (a) or (b) and which codes for a polypeptide according to claim 1 or 2, or a functionally equivalent modified form thereof.  
30

-41-



6. A vector which comprises the nucleic acid molecule according to claim 4 or 5.
- 5 7. A vector according to claim 6 which is the plasmid vector pAE1 (NCIMB 40732).
8. A vector according to claim 6 which is an expression vector capable of mediating the expression of a DNA molecule according to claim 4 or 5.
- 10 9. A vector according to claim 8 which is the plasmid vector pS863.
10. A host cell harbouring a vector according to any one of claims 6 to 9.
- 15 11. A process for production of a polypeptide which is a *Helicobacter pylori* surface-exposed 29 kDa antigen, which comprises culturing a host cell transformed with an expression vector according to claim 8 or 9 under conditions whereby said polypeptide is produced, and recovering said polypeptide.
- 20 12. A polypeptide or peptide according to any one of claims 1 to 3 for use in therapy.
13. A polypeptide or peptide according to any one of claims 1 to 3 for  
25 use in the diagnosis of *Helicobacter pylori* infection.
14. A polypeptide or peptide according to any one of claims 1 to 3 for use as a vaccine.

15. A vaccine composition for inducing a protective immune response to *Helicobacter pylori* infection, comprising an immunogenically effective amount of a polypeptide according to any one of claims 1 to 3, or a modified form of said polypeptide which retains the capability to induce protective immunity against *Helicobacter pylori* infection, optionally together with a pharmaceutically acceptable carrier or diluent.
16. A vaccine composition according to claim 15 for use as a therapeutic vaccine in a mammal, including man, which is infected by *Helicobacter pylori*.
17. A vaccine composition according to claim 15 for use as a prophylactic vaccine to protect a mammal, including man, from infection by *Helicobacter pylori*.
18. Use of a polypeptide according to any one of claims 1 to 3, or a modified form of said antigen which retains the capability to induce protective immunity against *Helicobacter pylori* infection, in the manufacture of a composition for the treatment, prophylaxis or diagnosis of *Helicobacter pylori* infection.
19. Use of a polypeptide according to any one of claims 1 to 3, or a modified form of said antigen which retains the capability to induce protective immunity against *Helicobacter pylori* infection, in the manufacture of a diagnostic kit for diagnosis of *Helicobacter pylori* infection.
20. Use of a polypeptide according to any one of claims 1 to 3, or a modified form of said polypeptide which retains the capability to induce protective immunity against *Helicobacter pylori* infection, in

the manufacture of a vaccine for use in eliciting a protective immune response against *Helicobacter pylori*.

- 5 21. A method of eliciting in a mammal a protective immune response against *Helicobacter pylori* infection, said method comprising the step of administering to the said mammal an immunologically effective amount of a vaccine composition according to any one of claims 15 to 17.
- 10 22. A method according to claim 21 wherein the said mammal is a human.
- 15 23. A method of *in vitro* diagnosis of *Helicobacter pylori* infection comprising at least one step wherein a polypeptide according to any one of claims 1 to 3, optionally labelled or coupled to a solid support, is used.
- 20 24. A method according to claim 23 comprising the steps  
(a) contacting a said polypeptide, optionally bound to a solid support, with a body fluid taken from a mammal; and  
(b) detecting antibodies from the said body fluid binding to the said polypeptide.
- 25 25. A diagnostic kit for the detection of *Helicobacter pylori* infection in a mammal, including man, comprising components which enable the method according to claim 23 or 24 to be carried out.

1 / 2

*Fig. 1**Fig. 2*

2 / 2

Fig. 3



Effect of Mab's on the colonisation of *H. pylori* in BALB/c mice

Fig. 4

Therapeutic oral immunization of *H. pylori* infected BALB/c mice



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 96/00727

## A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C07K 14/205 // A61K 39/106

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C07K, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, EDOC, MEDLINE, DBA, EMBL/GENBANK/DOB (STRAND), SCISEARCH

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EMBL, Gen Bank Accession no. X92502, Jones, A.C. et al: "Gene cloning of a flagellar sheath protein of Helicobacter pylori", Submitted (24-OCT-1995), & J. Bacteriol, 175 (3), 674-683 (1993) --	1-25
X	Microbiology, Volume 141, 1995, Catherine J. Luke et al, "Identification of a 29 kDa flagellar sheath protein in Helicobacter pylori using a murine monoclonal antibody" page 597 - page 604 --	1-25
X	Gut, Volume 37, No 1, 1995, A Jones et al, "Gene Cloning of a Flagellar Sheath Protein of Helicobacter Pylori" page 252 -- -----	1-25

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

## \* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\*&amp;\* document member of the same patent family

Date of the actual completion of the international search

4 Sept 1996

Date of mailing of the international search report

05 -09- 1996

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Patrick Andersson

Telephone No. +46 8 782 25 00

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 96/00727

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 21-22  
because they relate to subject matter not required to be searched by this Authority, namely:  
See PCT Rule 39.1(iv): Method for treatment of human or animal body.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(i).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.